LP 002 - Linton Pharm
Alternative Names: LP-002Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Linton Pharm
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in China (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in China (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in China (Parenteral)